There are 5 papers on advanced prostate cancer in aging research: 3 observational studies in people, 1 review.
5 papers study it40 more mention it5 findings
1 new paper in 30 daysSee all 45
“Compared to never-users, men who used multivitamin 10 or more tablets per week had similar risk of advanced (HR: 1.14, 95% CI: 0.77-1.70, Ptrend=0.46) or lethal”
- Humans3
- In silico1
Associations
5Triacylglycerols
upin humans1
1 study
Triacylglycerols
upin humans1
Triacylglycerols are associated with advanced prostate cancer in humans (P=2.4E-06).
“TAGs overall (P=2.4E-06).”
Humansmales
medRxivPreprint
Diacylglycerols
upin humans1
1 study
Diacylglycerols
upin humans1
Diacylglycerols are associated with advanced prostate cancer in humans (P=3.4E-07).
“Enrichment analyses revealed six metabolite classes associated with advanced prostate cancer after multiple testing adjustment, the top four of which were DAGs and TAGs”
Humansmales
medRxivPreprint
C38:4 diacylglycerol
upin humans1OR 1.27
1 study
C38:4 diacylglycerol
upin humans1OR 1.27
C38:4 diacylglycerol is linked with a higher risk of advanced prostate cancer in humans (OR: 1.27, 95%CI: 1.04-1.55).
“C38:4 diacylglycerol (DAG; OR: 1.27, 95%CI: 1.04-1.55).”
Humansmales
medRxivPreprint
C56:1 triacylglycerol
upin humans1OR 1.34
1 study
C56:1 triacylglycerol
upin humans1OR 1.34
C56:1 triacylglycerol is linked with a higher risk of advanced prostate cancer in humans (OR: 1.34, 95%CI: 1.07-1.67).
“The strongest signals were for C56:1 triacylglycerol (TAG; OR: 1.34, 95%CI: 1.07-1.67) and C38:4 diacylglycerol (DAG; OR: 1.27, 95%CI: 1.04-1.55).”
Humansmales
medRxivPreprint
Multivitamin
no changein humans1HR 1.14
1 study
Multivitamin
no changein humans1HR 1.14
Multivitamin is associated with advanced prostate cancer in humans (HR 1.14, 95% CI 0.77-1.70).
“Compared to never-users, men who used multivitamin 10 or more tablets per week had similar risk of advanced (HR: 1.14, 95% CI: 0.77-1.70, Ptrend=0.46) or lethal”
Humans10 or more tablets per weekmalesn = 48,137
The Journal of urology
Trial sponsors
Company1 trialPhase 2242 people
Company1 trialPhase 1/2212 people
Company1 trialPhase 1100 people
Universita degli Studi di Torino
1 trialPhase 3600 people
1 trialPhase 2202 people
1 trialEarly phase 117 people
Funding
3 grants since 2021Prostate Cancer Foundation